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Abstract 
Mutations of the extracellular domain of the insulin receptor impair processing and transport of receptors to the plasma membrane. We have 
previously reported that a mutation substituting Val for Phe 382 in the cl-subunit of the insulin receptor impairs intracellular processing and 
insulin-induced autophosphorylation of the mutant receptor. In this investigation, we have generated two independent mutations of amino acids Phe38’ 
and Phe’*’ of the insulin receptor: Val for Phe38’ and Leu for Phe’82. These substitutions cause a slight impairment of intracellular processing and 
transport of the mutant receptors. Furthermore, insulin-dependent internalization of the mutant receptors is unaffected by these mutations. Thus, 
of the three substitutions tudied to date, Val for Phe 382 is the only mutation of the Phe38’-Phe382 sequence that causes a major defect in post- 
translational processing of the receptor. 
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1. Introduction 
The insulin receptor belongs to a family of hormone 
receptors with tyrosine kinase activity [l]. Binding of 
insulin to the extracellular domain of the insulin receptor 
&-subunit riggers tyrosine phosphorylation of the intra- 
cellular domain of the p-subunit. Phosphorylation of 
other protein substrates by the receptor tyrosine kinase 
is thought to represent an important mechanism by 
which insulin exerts its actions on target cells [l]. 
Studies of mutations of the insulin receptor gene in 
patients with genetic forms of insulin resistance have 
provided valuable insights into structure-function rela- 
tionships of the insulin receptor. Several of the point 
mutations identified in the N-terminal half of the a-sub- 
unit are associated with defective processing of the insu- 
lin receptor precursor, and with an impaired rate of 
transport of mutant receptors to the plasma membrane 
[2-81. Defective transport is probably caused by a con- 
formational change in the secondary structure of the 
receptor that causes mutant receptors to be retained in 
the rough endoplasmic reticulum, where they are bound 
to the immunoglobulin binding protein BiP [4]. 
Furthermore, the conformational changes caused by 
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these point mutations can affect the function of the re- 
ceptor in other ways. For example, substitution of Lys 
for Asn” is associated with a reduced affinity of the 
receptor to bind insulin [5], and substitution of Val for 
Phe3” is associated with reduced insulin-induced phos- 
phorylation of the p-subunit [9, IO]. 
Substitution of Val for Phe382 was the first mutation 
reported to interfere with transport of the insulin recep- 
tor to the cell surface [3]. In the present study, we have 
used site-directed mutagenesis to further analyze the ef- 
fect of replacing amino acids Phe3*l and Phe382 in the 
primary sequence of the insulin receptor. We have re- 
placed Phe382 with Leu, the corresponding amino acid 
found in the sequence of the highly homologous receptor 
for insulin-like growth factor-I (IGF-I) [ll]. Further- 
more, we have changed the preceding amino acid in the 
primary sequence of the insulin receptor, Phe381, to Val. 
Unlike the Va13*’ mutation, the Phe38’ and the Leu382 
substitutions caused little if any defect in processing and 
transport of mutant receptors to the plasma membrane. 
2. Materials and methods 
2.1. Cell lines 
NIH-3T3 fibroblasts transfected with expression plasmids encoding 
the wild-type human insulin receptor (WT) or the Va1382 mutant recep- 
tor (Va1382) have been described in previous studies [3,4,9]. Expression 
vectors for the Val’*‘- or Leu”’ -mutant insulin receptors were generated 
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by oligonucleotide-directed mutagenesis of the human insulin receptor 
cDNA [ 121. In the Val”’ construct, codon 381 (lTCphe) was replaced 
by GTC?’ using a mutagenic oligonucleotide corresponding to nucleo- 
tides 1,263_1,2i4 of the-human;nsulin receptor cDNA, in the L&*2 
construct. codon 382 (TTCphej was reDlaced bv CTCL”” using a mut- 
agenic oligonucleotide ‘corresponding ti the same cDNA seque&e indi- 
cated above. Mutant cDNAs were then cloned in a SV40-based expres- 
sion plasmid and transfected in NIH 3T3 cells as described before [3]. 
The presence of the point mutations at codons 381 and 382 was con- 
firmed using a reverse transcriptase/polymerase chain reaction assay 
IRT/FCR) to amplify a fragment of human insulin receptor cDNA 
encompassing nucleotides 1,199-l ,308 [ 121 as described previously [3]. 
Direct sequencing of PCR-amplified cDNA was performed as de- 
scribed previously [13]. 
-7.2. [‘-‘sI]Insulin binding assay 
[‘ZSI]Insulin binding assays were performed on confluent monolayers 
of intact cells as described previously [3]. To determine the intemaliia- 
tion rates, binding assays were performed overnight at 4°C and un- 
bound insulin was removed by washing with ice-cold PBS. Thereafter, 
binding assay medium was added, and the cells were transferred to a 
37°C incubator for varying periods of time. At each time point, insulin 
that remained at the cell surface was removed by an acid wash with a 
binding assay solution at pH 4.5, and internalized insulin was deter- 
mined separately by lysing cells in NaOH [5]. 
2.3. Biosynthetic labeling 
Confluent monolayers of transfected cells were incubated for 1 h in 
methionine-free DMEM. Thereafter, cells were incubated in complete 
medium containing 0.1 mCi/ml of [35S]methionine (1,100 Ci/mmol; Du- 
pont-NEN, Wilmington, DE) for 1 h at 37”C, followed by a chase 
period of up to 24 h in complete medium. At each time point during 
the chase period, cells were harvested and processed for immunoprecip- 
itation and gel electrophoresis as described previously [3]. 
3. Results 
NIH 3T3 cells transfected with expression vectors en- 
coding wild-type or Va1382-, Va1381-, or Leu382-mutant in- 
sulin receptor cDNA were assayed for [“‘I]insulin bind- 
ing to cell surface receptors (Fig. 1). One clone express- 
ing each type of receptor was selected for further studies. 
Sequence analysis of amplified cDNA derived from 
transfected cell lines confirmed the presence of the point 
mutations introduced at positions 38 1 and 382 (data not 
shown). Scatchard analysis of binding data indicated 
that insulin binding affinity was unaffected by mutations 
substituting Val for Phe381, Val for Phe382 and Leu for 
Phe3** (not shown). 
3.1. Metabolic labeling experiments 
Substitution of Val for Phe382 impairs processing of the 
insulin receptor and its transport to the plasma mem- 
brane [3,4]. To study the effect of substituting Val for 
Phe3*’ or Leu for Phe382 on receptor processing, pulse- 
chase labeling experiments with [35S]methionine were 
performed on transfected cells (Fig. 2). After labeling the 
cells, receptors were solubilized with Triton X-100 and 
immunoprecipitated with anti-receptor antibody. The 
wild-type insulin receptor is synthesized as a single-chain 
glycoprotein precursor with M, = 190,000. This product 
undergoes several post-translational modifications, in- 
cluding proteolytic cleavage into cx- and B-subunits and 
Insulin (ng/ml) 
Fig. 1. [“‘IjInsulin binding to cells transfected with wild-type and mu- 
tant insulin receptors. Monolayer cultures of NIH 3T3 cells transfected 
with wild-type, Va13”-, Leu382-, orVal’*‘-mutant insulin receptor cDNA 
were incubated overnight with [‘251]insulin in the presence of increasing 
concentrations of unlabeled insulin. Unbound insulin was removed by 
washing monolayers with ice-cold PBS, and radioactivity was deter- 
mined on total cellular lysates in a gamma counter. The amount of 
tracer bound in the absence of unlabeled ligand was normalized to 
100%. 
N-linked glycosylation [14-161. Cleavage of the precur- 
sor into separate subunits and maturation of the N- 
linked carbohydrate side chains occur virtually simulta- 
neously in cells transfected with wild-type receptors, so 
that 01- and j&subunits are visualized as single bands of 
M, 135,000 and 95,000, respectively (Fig. 2, lanes l-6). 
As shown previously [3,4], post-translational processing 
of the insulin receptor is substantially retarded by substi- 
tution of Val for Phe382. This retarded processing is re- 
flected by the appearance of a characteristic doublet of 
bands in the region of the gel corresponding to a- and 
j?-subunits, due to the presence of incompletely proc- 
essed pre-a and pre$-subunits (Fig. 2, lanes 7-12) [3-61. 
Interestingly, the Va1381- and the Leu382-mutant receptors 
showed only a slight retardation of the processing rate. 
In cells transfected with the VaP8’ receptor, mature a- 
and B-subunits could only be visualized at 4 h and not 
at 1 h of chase (compare Fig. 2, lanes 1,2 and 13-15). 
Likewise, processing of the Leu382 receptor was retarded 
when compared to the wild-type receptor, so that at 1 h 
of chase only pre-a- and pre-/3-subunits could be seen 
(Fig. 2, lanes 19-21). In contrast to the Va1382 receptor, 
pre-c+ and pre-/3-subunits disappeared after 1 h, whereas 
they persisted for up to 12 h in Va1382-transfected c lls 
(Fig. 2, lanes 7-11). Similar data were obtained when 
processing of the carbohydrate side chains was studied 
with [3H]mannose labeling followed by endoglycosidase 
H digestion (data not shown). 
3.2. Internalization of the insulin-receptor complex 
Following insulin binding, the insulin-receptor com- 
plex is internalized through clathrin-coated pits into en- 
docytic vesicles [17]. We wanted to determine whether 
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Fig. 2. Biosynthetic labeling of insulin receptors with [‘5S]methionine. Transfected cells were incubated for 1 h in methionine-free DMEM and then 
pulse-labeled for 1 h in the presence of 0.1 mCl/ml of [“Slmethionine. Thereafter, the medium was changed to complete DMEM and the incubation 
was continued for 1 to 24 h. At the end of each time point, cells were removed from the dishes by lysis in a buffer containing 1% Triton X-100. Lysates 
were immunoprecipitated using an anti-insulin receptor antibody or non-immune rabbit serum as described in section 2. Lanes l-6, wild-type insulin 
receptor; lanes 7-12, Val’82-mutant; lanes 13-18, L~u’*~- mutant; lanes 19-24. Va138’-mutant. 
mutations at positions 381 and 382 in the extracellular 
domain would interfere with the endocytic pathway. 
[1251]Insulin was allowed to bind to cell surface receptors 
for 16 h at 4°C. Under these conditions, no significant 
internalization occurs. Thereafter, cells were incubated 
at 37°C to allow for endocytosis of the hormone-recep- 
tor complex. [‘*‘I]Insulin that remained bound to the cell 
surface was removed by an acid wash (pH 4.5). [1251]Insu- 
lin disappeared from the cell surface at approximately 
the same rate in cells expressing ail four types of recep- 
tors (Fig. 3A). After incubation for 5 min at 37°C cell 
surface radioactivity had declined to approximately 40% 
of its initial value. Internalized insulin was measured as 
radioactivity that remained cell-associated after the acid 
wash (Fig. 3B) [5]. Within 20 min, approximately 40% 
of [“‘I]insulin was internalized into cells expressing the 
wild-type insulin receptor (Fig. 2B). Interestingly, the 
three mutant receptors (Va13”, Leu382, and Va13*‘) had 
internalization kinetics that were nearly identical to the 
wild-type receptor (Fig. 3A,B). The Va1382 and Leu382 
receptors were virtually indistinguishable from the wild- 
type receptor, while a small difference was observed in 
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the amount of insulin internalized into cells transfected 
with the VaP8’ receptor (Fig. 3B). The rate of dissappear- 
ante of the tracer from the cell surface was, however, 
similar to that observed in the other three cell lines (Fig. 
3A). 
4. Discussion 
Mutations of the extracellular domain of the insulin 
receptor have been identified in patients with genetic 
forms of insulin resistance [2]. These mutations localize 
to the N-terminal half of the a-subunit of the insulin 
receptor and interfere with multiple aspects of insulin 
receptor function: processing of the proreceptor, trans- 
port to the plasma membrane, insulin binding, and recy- 
cling of the insulin-receptor complex. Transport-defec- 
tive mutants of the insulin receptor are generally the 
result of single amino acid substitutions in the receptor’s 
extracellular domain. It has been proposed that the pres- 
ence of point mutations in this region of the receptor may 
affect folding of the receptor molecule and prevent intra- 
cellular processing and transport to the plasma mem- 
6 
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Fig. 3. Insulin-induced internalization of the hormone-receptor complex. Transfected cells were incubated overnight with [“‘I]insulin at 4°C. 
Thereafter, unbound insulin was removed by washing twice with ice-cold PBS, and 2 ml of a binding assay solution [8] (pH 7.4) were added. Cells 
were transferred to a 37°C incubator, and the incubation was continued for up to 1 h. At each time point, cells were washed again and then incubated 
in binding assay solution at pH 4.5. After 30 min, the solution was removed and counted in a gamma counter (A). Cell- associated radioactivity was 
also measured by solubilizing monolayers in 1 N NaOH (B) [5]. 
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brane of the mutant receptors. In some instances it has 
been possible to show that mutant receptors are associ- 
ated with the immunoglobulin binding protein BiP in the 
rough endoplasmic reticulum [4]. Because BiP has im- 
portant functions, including to catalyze folding and mul- 
timerization of nascent polypeptide chains and also to 
retain misfolded mutant proteins in the endoplasmic 
reticulum, this finding has led to the suggestion that 
binding to BiP may represent he mechanism that inhib- 
its transport of mutant insulin receptors to the cell sur- 
face [4]. Similar findings have now been reported for 
other mutations associated with human diseases, like 
cystic fibrosis [18] and osteogenesis mperfecta [19]. 
In the present study, we have extended our character- 
ization of mutations of the extracellular domain of the 
insulin receptor by generating two site-directed mutants 
of the sequence Phe381-Phe382 : Va13*l and Leu3**. This 
double phenylalanine motif is highly conserved in the 
family of receptors homologous to the insulin and EGF 
receptor: human and guinea pig insulin receptor-related 
receptor [20], human and Drosophila EGF receptor 
[21,22], and c-erb-B2 protein [23]. However, the closely 
related IGF-1 receptor differs at this position within an 
otherwise highly conserved sequence [l 11. In the se- 
quence of the IGF-1 receptor, leucine is found at the 
homologous amino acid residue (Leu3’*). In the insulin 
receptor, replacement of Phe3** by Leu exerts a minimal 
effect on intracellular processing and transport of the 
insulin receptor. Thus, the impairment in receptor func- 
tion is specifically associated with the presence of the 
amino acid residue Val at position 382. Our observation 
that substitution of Val for Phe3*’ also does not affect 
receptor function in a major way suggests that Phe382 
plays a more important role in receptor folding and sta- 
bilizing the native conformation of the receptor. Interest- 
ingly, Val is found at the amino acid residue homologous 
to Phe381 of the c-erb-B2 receptor (Va1424) [23]. These 
observations are also consistent with the conclusion that 
there is not a requirement for two adjacent aromatic 
amino acid residues at this location to stabilize the con- 
formation of the insulin receptor and other homologous 
receptors. 
It is not clear why there is a difference between the 
Va13**- and the VaP81- and Leu3**-mutant receptors. The 
presence of Val at amino acid residue 382 might cause 
the mutant receptor to bind more tightly to the immu- 
noglobulin binding protein BiP so that it would be im- 
paired in its ability to be transported from the endoplas- 
mic reticulum through the Golgi to the plasma mem- 
brane [4]. Available data are not adequate to answer this 
question. However, studies of the interaction between 
small peptides and BiP suggest hat the presence of leuc- 
ine residues in random peptides (composed of up to 
seven amino acids) tends to increase the potency of the 
peptides in stimulating the ATPase activity of the BiP 
protein. This suggests that the presence of leucine tends 
to enhance the ability of a peptide to interact produc- 
tively with the BiP protein. While other hydrophobic 
amino acids are also found with increased frequency in 
the binding site of BiP, the affiity of a random peptide 
containing Leu at any given position is higher than that 
of a similar peptide containing Val or Phe in the same 
position [24]. 
4.1. Va1382-mutant receptor undergoes normal 
ligand-induced endocytosis 
Previous studies with site-directed mutants of the insu- 
lin receptor have suggested that receptor tyrosine kinase 
activity is required for ligand-stimulated internalization 
of receptors [16,25-301. Because we had previously 
shown that the Va13**-mutation impaired receptor auto- 
phosphorylation [9,10] we wished to investigate receptor- 
mediated endocytosis of Va13*‘-, VaP8*-, and Leu3**-mu- 
tant receptors. We did not detect major differences be- 
tween the internalization rates of wild-type and mutant 
receptors. It is not clear why the Va13’* mutation differs 
in this respect from other mutations that impair receptor 
autophosphorylation. However, it is intriguing that the 
other mutations mapped to the intracellular domain of 
the receptor while the Va1382 mutation is located in the 
extracellular domain. Our observations raise the possi- 
bility that the inhibition of endocytosis is not due to the 
defect in receptor autophosphorylation per se, but to an 
associated abnormality in the conformation of the intra- 
cellular domain. 
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